Lipid transfer proteins:consequences for cellular cholesterol efflux and cardiovascular risk in diabetes mellitus by de Vries, Rindert
  
 University of Groningen
Lipid transfer proteins
Vries, Rindert de
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2009
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Vries, R. D. (2009). Lipid transfer proteins: consequences for cellular cholesterol efflux and cardiovascular
risk in diabetes mellitus. s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
CHAPTER 7
ELEVATED PLASMA PHOSPHOLIPID TRANSFER 
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CAROTID INTIMA-MEDIA THICKNESS 
IN TYPE 2 DIABETES MELLITUS
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A. van Tol1,4 , R.P.F. Dullaart1
1 Department of Endocrinology, 
2 Department of Internal Medicine, University Medical Center Groningen, 
University of Groningen, Th e Netherlands 
3 Laboratory of Vascular Medicine, 
4 Department of Cell Biology & Genetics, Erasmus University Medical Center, 











Th e plasma activity of phospholipid transfer protein (PLTP), which has putative pro- 
and anti-atherogenic roles in lipoprotein metabolism, is increased in type 2 diabetes 
mellitus. We analysed the relationship of carotid artery intima-media thickness (IMT), 
an established marker of atherosclerosis, and PLTP activity in diabetic and in control 
subjects. 
Methods
Th e IMT (mean of 3 segments in both carotid arteries by ultrasonography), clinical 
variables, plasma PLTP activity (phospholipid vesicles-HDL system), lipoproteins, C-
reactive protein and insulin were measured in 87 non-smoking men and women who 
had type 2 diabetes mellitus no cardiovascular disease, and were not on insulin or lipid 
lowering medication and 83 age-matched control subjects. 
Results
In diabetic patients, carotid IMT (p = 0.02), pulse pressure (p = 0.003), plasma PLTP 
activity (p < 0.001), triglycerides (p = 0.01), C-reactive protein (p < 0.01) and insulin (p 
< 0.001) were higher, whereas HDL cholesterol was lower (p < 0.001) than in control 
subjects. Multiple stepwise linear regression analysis demonstrated that in type 2 diabetic 
patients IMT was independently associated with age (p < 0.001), sex (p = 0.001), pulse 
pressure (p = 0.003), plasma PLTP activity (p = 0.03) and HDL cholesterol (p = 0.03), 
but not with very low density lipoprotein+LDL cholesterol, triglycerides, C-reactive 
protein and insulin (all p > 0.20). Th e relationship between plasma PLTP activity and 
IMT was not signiﬁ cant in control subjects. 
Conclusion/interpretation
Plasma PLTP activity is a positive determinant of IMT in type 2 diabetes mellitus, 
suggesting that high PLTP activity is involved in accelerated atherosclerosis in this 
disease. 
Keywords: phospholipid transfer protein, high density lipoprotein, C-reactive protein, 
intima-media thickness, type 2 diabetes mellitus
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INTRODUCTION
Th e multifunctional role of phospholipid transfer protein (PLTP) in lipoprotein 
metabolism is increasingly recognised. PLTP facilitates the transfer of phospholipids and 
free cholesterol from the surface of triglyceride-rich lipoproteins towards HDL particles 
during intravascular lipolysis [1,2]. Furthermore, PLTP is able to convert HDL3 into 
larger and smaller particles [3], generating small lipid-poor pre β-HDL particles [4,5] 
that may act as initial acceptors of cell-derived cholesterol. Over-expression of PLTP 
enhances pre β-HDL formation [6], thereby stimulating cholesterol removal and 
preventing cholesterol accumulation in macrophages [7]. Besides these potentially 
anti-atherogenic actions, PLTP also has pro-atherogenic potential, as evidenced by 
stimulation of hepatic apolipoprotein (apo) B secretion and by eﬀ ects on HDL levels 
in mouse models [8-10]. Moreover, PLTP has the ability to transfer the anti-oxidant α-
tocopherol between lipoproteins, and it has been demonstrated that experimental PLTP 
deﬁ ciency results in an increased α-tocopherol content of LDL, thereby protecting these 
lipoproteins against oxidation [11]. 
Experimental ﬁ ndings suggest that the overall eﬀ ect of PLTP is likely to be pro-
atherogenic. Atherosclerosis development is accelerated in mice over-expressing human 
PLTP [9,12], but is attenuated in PLTP knockout models [10]. Little is known about 
the relationship between plasma PLTP activity and cardiovascular disease in humans. 
One cross-sectional study demonstrated that the plasma PLTP activity level was higher 
in patients with coronary artery disease than in subjects recruited from the general 
population [13]. 
We and others have previously found that plasma PLTP activity is increased in 
obese subjects [14-16], and is metabolically linked to triglyceride and NEFA metabolism 
[14,15,17]. Interestingly, several reports have shown that plasma PLTP activity is elevated 
in type 2 diabetes mellitus [15,17-19] although most of these studies were performed in 
small numbers of subjects. Taken together, these ﬁ ndings suggest that high plasma PLTP 
activity could contribute to increased atherosclerosis in type 2 diabetic patients.
Th e present study was initiated to test the hypothesis that in type 2 diabetes 
mellitus the level of plasma PLTP activity is a determinant of carotid intima-media 










Th e study protocol was approved by the local medical ethics committee of 
the University Medical Center Groningen and written informed consent was obtained 
from each participant. Type 2 diabetic patients and age-matched non-diabetic control 
subjects were recruited by advertisement in local newspapers. Type 2 diabetes mellitus 
was previously diagnosed using blood glucose thresholds as deﬁ ned by the WHO. Only 
non-smoking subjects, aged over 18 years were included. Subjects currently or previously 
taking lipid-lowering drugs were excluded from participation in order to avoid bias due 
to eﬀ ects of such medication on lipoprotein metabolism as well as on IMT progression. 
Insulin treatment was also an exclusion criterion. None of the participants had clinically 
manifest cardiovascular disease, and urinary albumin concentration was < 20 mg/l in all 
of them. In diabetic patients (treatment for) hypertension was allowed. Maximal alcohol 
intake was 3 drinks per day, a brink being deﬁ ned as 250 ml beer, 100 ml wine or 35 
ml spirits. 
All participants were evaluated after an overnight fast at the Laboratory of 
Vascular Medicine. BMI was calculated as weight divided by height squared. Waist 
circumference was measured as the smallest circumference between rib cage and iliac 
crest. Systolic and diastolic blood pressure were measured after at least 15 minutes of 
rest at the left arm in sitting position using a sphygmomanometer. Pulse pressure was 
calculated as the diﬀ erence between systolic and diastolic blood pressure. 
Carotid IMT measurement
IMT of the carotid arteries was measured by ultrasonography in the supine 
position. Well-trained sonographers not informed about subject disease state scanned 
high-resolution B-mode ultrasound images (ACUSON 128 XP, Mountain View, CA, 
USA) with a 7.5 MHz linear array transducer. Th ree arterial wall segments in each carotid 
artery were imaged from a ﬁ xed lateral transducer angle at the far wall. Th e segments 
scanned were the segment 1 cm proximal to the carotid dilatation (common carotid 
artery), the segment between the carotid dilatation and carotid ﬂ ow divider (carotid 
bulb) and a 1 cm segment distal to the ﬂ ow divider (internal carotid artery). Th e scans 
were recorded on S-VHS tape and analyzed oﬀ -line by an independent image analyst 
who was unaware of subjects characteristics. B-mode image analyses were digitized with 
a frame grabber (DT286 l; Data Translation Inc.; Marlboro, MA). Th e image analysis 
software was developed using an algorithm as developed by Selzer et al [21]. Th e mean 
IMT over the six segments of both carotid arteries was calculated and was designated 
w
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mean IMT. At a mean IMT of 0.80 mm, inter-sonographer variability amounted to 
0.05 mm, with an image analyst variability of less than 0.03 mm, corresponding to a 
total variation coeﬃ  cient between 6.3% and 7.3%. 
Laboratory measurements
Venous blood samples for measurement of apo and PLTP activity were collected 
into EDTA-containing tubes (1.5 mg/ml) and placed on ice immediately. Plasma was 
obtained within 30 min by centrifugation at 1400 g for 15 min at 4˚C. Samples were 
kept frozen at -80˚C until analysis.
Plasma total cholesterol and triglycerides were assayed by routine enzymatic 
methods (Roche/Hitachi cat nos 11876023 and 11875540 respectively, Roche Diagnostics 
GmbH, Mannheim, Germany). HDL cholesterol was determined in the supernatant 
fraction after precipitation of VLDL + LDL lipids with polyethylene glycol-6000. VLDL 
+ LDL cholesterol was calculated by subtracting plasma HDL cholesterol from plasma 
total cholesterol. Apolipoprotein A-I and apo B were measured by immunoturbidimetry 
(Roche /Cobas Integra Tina-quant cat nos 03032566 and 03032574 respectively, Roche 
Diagnostics GmbH, Mannheim, Germany). Plasma PLTP activity was assayed using a 
phospholipid vesicles-HDL system, as previously described [14,22], using [14C]-labelled 
dipalmitoyl phosphatidylcholine. In short, small plasma samples (1 μl) were incubated 
with [14C]-phosphatidylcholine-labelled phosphatidylcholine vesicles and excess pooled 
normal HDL for 45 min at 37˚C. Th e vesicles were then precipitated using a mixture of 
NaCl, MgCl2 and heparin (ﬁ nal concentrations: 230 mmol/l, 92 mmol/l and 200 IU/ml, 
respectively). Th e PLTP activity levels vary linearly with the amount of plasma added to 
the incubation system. Th is method is speciﬁ c for PLTP activity and the phospholipid 
transfer promoting property of cholesteryl ester transfer protein (CETP) does not 
interfere with the assay [22]. Plasma PLTP activity is related to the activity in human 
reference pool plasma and is expressed in arbitrary units (AU; 100 AU corresponds to 
13.6 μmol phosphatidylcholine transferred per litre per hour).
Glucose was analysed with an APEC glucose analyzer (APEC Inc., Danvers, 
MA). Glycated haemoglobin was measured by HPLC (Bio-Rad, Veenendaal, Th e 
Netherlands; normal range 4.6-6.1%).
Plasma C-reactive protein (CRP) was determined by nephelometry with a 
threshold of 0.175 mg/l (BNII N; Dade Behring, Marburg, Germany).
Plasma insulin levels were assessed using a microparticle enzyme immunoassay 









Parameters with a normal distribution are given as mean ± SD. Parameters with 
a skewed distribution are given as median (interquartile range). Data were compared 
using unpaired t-tests or Mann-Whitney U-tests where appropriate. To evaluate 
diﬀ erences in proportions of parameters, we used χ2 analysis. Multiple (stepwise) linear 
regression analysis was used to disclose independent relationships between variables. 
When a variable was not normally distributed, logarithmically transformed values of 
this variable were used in the models. Th e relative contributions of variables in the 
regression models were expressed as the IMT eﬀ ect, which was estimated by multiplying 
regression coeﬃ  cient B with the SD of the independent variable of interest included in 
the model, as well as the partial correlation coeﬃ  cients. Th e IMT dimension as shown 
in Fig. 1 is normalised to the mean age in each group, applying regression coeﬃ  cients 
as determined by univariate linear regression analysis. Two-sided p values less than 0.05 























< median >/= median
Figure 1. Age-normalised mean intima media thickness (IMT) according to plasma phospholipid transfer 
protein (PLTP) activity in type 2 diabetic patients (shaded bars) and control subjects (open bars).
Bars indicate mean ± SEM
w
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RESULTS
Th e study included 87 type 2 diabetic patients and 83 control subjects. Th ere 
was no diﬀ erence in sex distribution between the type 2 diabetic patients and control 
subjects (p = 0.47). Among control and diabetic women, 65 and 79% respectively were 
postmenopausal (p = 0.18). Median diabetes duration in type 2 diabetic patients was 
5.4 years. Patients were treated with diet alone (26%) or in combination with oral 
glucose-lowering agents (74%). Patients using oral glucose-lowering drugs were treated 
by sulfonylurea (33%), biguanides (26%) or the combination of these two (41%). 
In addition to these drugs, 8 patients used a thiazolidinedione and 2 patients used 
acarbose, an α-glucosidase inhibitor. Forty-four percent of diabetic patients but none of 
the control subjects used one or more antihypertensive drugs. Twenty-one patients used 
an ACE-inhibitor, either alone (n = 9) or in combination with a β-blocker, a calcium-
antagonist and/or a diuretic (n = 12). Seven patients used an agiotensin II antagonist in 
combination with other antihypertensive drugs. Ten patients used a β-blocker alone (n = 
7), a diuretic alone (n = 2) or a β-blocker in combination with a calciumantagonist (n = 
1). As shown in Table 1, age was similar in diabetic patients and control subjects. Body 
mass index, waist circumference, systolic and diastolic blood pressure, pulse pressure, 
fasting glucose, HbA1c, plasma CRP and insulin were all higher in type 2 diabetic 
patients. Th e carotid mean IMT was higher in type 2 diabetic patients than in control 
subjects. 
Table 1. Clinical characteristics and mean carotid artery intima media thickness (IMT) in type 2 diabetic 
patients and control subjects





Age (year) 57.9 ± 9.0 55.8 ± 9.4 0.15
Gender (M/F) 53/34 46/37 0.47
Diabetes duration (years) 5.4 (4.0 – 6.4) N.A.
Mean mean carotid IMT (mm) 0.876 ± 0.203 0.814 ± 0.144 0.02
Body mass index (kg/m2) 29.0 ± 5.1 25.7 ± 3.6 <0.001
Waist circumference (cm) 101.1 ± 13.4 88.7 ± 12.9 <0.001
Systolic BP (mmHg) 143.3 ± 19.0 131.8 ± 18.8 <0.001
Diastolic BP (mmHg) 86.8 ± 8.7 82.5 ± 10.7 <0.001
Pulse pressure (mmHg) 56.5 ± 16.5 49.3 ± 13.9 0.003
Fasting glucose (mmol/l) 8.8 ± 2.2 5.6 ± 0.7 <0.001
Plasma insulin (μU/ml) 6.0 (4.5 - 8.4) 9.6 (6.7 – 15.2) <0.001
HbA1c (%) 6.8 ± 1.0 5.3 ± 0.4 <0.001
CRP (mg/l) 1.24 (0.50 – 2.44) 1.74 (1.01 – 4.23) <0.001








Plasma total cholesterol was slightly lower in type 2 diabetic patients compared 
with control subjects (Table 2), but VLDL + LDL cholesterol and plasma apo B levels 
were not diﬀ erent between the two groups. In type 2 diabetic patients, plasma triglycerides 
were higher, whereas HDL cholesterol and plasma apo A-I were lower than in control 
subjects.  Plasma PLTP activity was higher in type 2 diabetic patients compared with 
control subjects (Table 2).
Table 2. Plasma lipid parameters and phospholipid transfer protein (PLTP) activity in type 2 diabetic 
patients and control subjects 






Plasma total cholesterol (mmol/l) 5.34 ± 0.89 5.74 ± 0.98 0.005
VLDL + LDL cholesterol (mmol/l) 4.09 ± 0.97 4.24 ± 1.05 0.35
HDL cholesterol (mmol/l) 1.35 ± 0.36 1.64 ± 0.42 <0.001
Plasma triglycerides (mmol/l) 1.71 (1.18 – 2.34) 1.30 (0.88 – 1.93) 0.01
Plasma apo A-I (g/l) 1.32 ± 0.23 1.43 ± 0.23 0.002
Plasma apo B (g/l) 0.92 ± 0.21 0.96 ± 0.24 0.34
Plasma PLTP activity (AU) 103.4 ± 11.6 94.7 ± 10.0 <0.001
Data in mean ± SD or median (interquartile range)
Multiple stepwise linear regression analysis was performed in the combined 
groups to assess whether plasma PLTP activity was still higher in the diabetic state after 
controlling for diabetes-related diﬀ erences in obesity and plasma lipid levels. In this 
analysis plasma PLTP activity was independently and positively associated with the 
presence of type 2 diabetes mellitus (p < 0.001), waist circumference (p < 0.001), HDL 
cholesterol (p = 0.001) and plasma triglycerides (p = 0.008, multiple r = 0.56). Plasma 
PLTP activity was not independently related to plasma insulin (p = 0.22), CRP (p = 
0.72) and VLDL + LDL cholesterol (p = 0.99). When diabetic patients were evaluated 
separately, plasma PLTP activity was positively related to waist circumference (p < 0.001), 
plasma insulin (p = 0.003), HDL cholesterol (p = 0.003, multiple r = 0.56), but not with 
fasting glucose (p = 0.19), plasma triglycerides (p = 0.42), the use of anti-hypertensive 
medication (p = 0.52) and VLDL + LDL cholesterol (p = 0.55). Th e positive relationship 
with HbA1c was nearly signiﬁ cant (p = 0.07).
In each group, multiple stepwise linear regression analysis was also applied to 
evaluate the independent contribution of age, sex, haemodynamic parameters, lipid 
variables, including HDL cholesterol, VLDL + LDL cholesterol (or alternatively plasma 
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Age and sex are well-known to be important determinants of IMT [23]. Besides age and 
sex, systemic haemodynamic factors positively aﬀ ect IMT [24]. Of the various parameters 
reﬂ ecting blood pressure, pulse pressure was the best ﬁ tting variable in the present study. 
We, therefore, included age, sex and pulse pressure in the model when evaluating the 
relationships of plasma PLTP activity and other laboratory parameters with IMT. Th e 
independent determinants of IMT in each group are shown in Table 3 and 4. In type 2 
diabetic patients, plasma PLTP activity was a positive determinant of IMT independent 
from age, sex, pulse pressure and HDL cholesterol (multiple r = 0.71), whereas there 
were no independent relationships of IMT with plasma CRP (p = 0.18), insulin (p = 
0.24), VLDL + LDL cholesterol (p = 0.63) and triglycerides (p = 0.99). In this model, the 
contribution of plasma PLTP activity to carotid IMT was comparable to that of HDL 
cholesterol as reﬂ ected by a similar IMT eﬀ ect and a similar partial r-value (Table 3).
Table 3. Multiple linear regression models showing independent determinants of mean carotid artery 
intima media thickness (IMT) in 87 type 2 diabetic patients 
B p partial r IMT eﬀ ect
Constant -0.10 0.58
Age (years) 9.24 . 10-3 <0.001 0.39 8.18 . 10-2
Gender (men vs women) 11.6 . 10-2 0.001 0.25 11.6 . 10-2
Pulse pressure (mmHg) 3.11 . 10-3 0.003 0.30 5.13 . 10-2
Plasma PLTP activity (AU) 3.03 . 10-3 0.03 0.23 5.00 . 10-2
HDL cholesterol (mmol/l) -9.45 . 10-2 0.03 -0.24 -3.37 . 10-2
B = regression coeﬃ  cient or constant
IMT eﬀ ect : IMT eﬀ ect in mm per 1 SD of the mean value for continuous variables or for men vs women
Plasma PLTP activity was also an independent determinant of IMT (p = 0.04) when 
plasma apo A-I (p = 0.86) and apo B (p = 0.72) instead of HDL cholesterol and VLDL 
+ LDL cholesterol were included in the model (data not shown). In control subjects, 
IMT was determined by age, sex, pulse pressure and plasma triglycerides (multiple r = 
0.67, Table 4). In these subjects, there were no independent relationships of IMT with 
plasma PLTP activity (p = 0.60), CRP (p = 0.89), insulin (p = 0.42), HDL cholesterol (p 
=0.82) and VLDL + LDL cholesterol (p = 0.94) or alternatively with plasma apo A-I (p = 
0.84) and apo B (p = 0.39). Figure 1 shows the IMT normalised to the mean age in each 
group according to plasma PLTP activity in diabetic and control subjects. Additional 
analyses in the combined groups demonstrated neither an interaction between plasma 
PLTP activity and the diabetic state with respect to IMT (p = 0.44) nor a non-linear 








Table 4. Multiple linear regression models showing independent determinants of mean carotid artery 
intima media thickness (IMT) in 83 control subjects 
B P partial r IMT eﬀ ect
Constant 0.28 0.001
Age (years) 5.48 . 10-3 <0.001 0.40 5.12 . 10-2
Gender (men vs women) 5.84 . 10-2 0.03 0.24 5.84 . 10-2
Pulse pressure (mmHg) 3.75 . 10-3 <0.001 0.41 5.19 . 10-2
Plasma triglycerides 
(mmol/l, log-transformed)
11.7 . 10-2 0.03 0.24 2.68 . 10-2
B = regression coeﬃ  cient or constant
IMT eﬀ ect : IMT eﬀ ect in mm per 1 SD of the mean value for continuous variables or for men vs women
DISCUSSION
Th e main new ﬁ nding of this study is that carotid artery IMT is positively 
associated with plasma PLTP activity in type 2 diabetic patients. Th e magnitude of 
the eﬀ ect of plasma PLTP activity on IMT was similar to that of HDL cholesterol, 
which was negatively related to IMT. Moreover, plasma PLTP activity was higher in 
type 2 diabetes, even after adjustment for waist circumference, plasma lipid levels, 
HDL cholesterol, triglycerides, CRP and insulin. Th erefore, the present results are in 
agreement with the hypothesis that a higher plasma PLTP activity is a determinant of 
greater IMT in type 2 diabetes mellitus. Our ﬁ ndings suggest that plasma PLTP activity 
could play a role in increased cardiovascular risk observed in this disease.
Ultrasonographically measured carotid artery IMT is an accepted marker for 
subclinical atherosclerosis [20], and is a predictor of coronary artery disease and stroke 
both in non-diabetic and in diabetic populations [25-28]. As expected, patients with 
type 2 diabets included in the present study had a greater IMT than non-diabetic 
control subjects [29,30]. Th e magnitude of the diﬀ erence in IMT between diabetic 
patients and control subjects was similar compared to that in previous large-scale studies 
in which IMT was measured by a comparable method [31,32]. Male gender and age are 
important determinants of IMT, as unequivocally shown in the ARIC study [23] and 
conﬁ rmed in this report. Systemic haemodynamic factors also contribute to enhanced 
intima-media thickening [33]. Blood pressure is an important modiﬁ able risk factor 
for carotid artery IMT [34]. In our study, pulse pressure, which was higher in diabetic 
patients, was the strongest single haemodynamic variable associated with IMT. Pulse 
pressure is known to reﬂ ect arterial stiﬀ ness [35], which is higher in diabetic patients 
w
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[36]. In the present study, of the conventional lipoprotein parameters, HDL cholesterol 
and plasma triglyceride levels were determinants of IMT in the diabetic patients and 
control subjects, respectively. While the relationships of these two lipid parameters with 
IMT have been documented previously [37,38], the eﬀ ects of VLDL+LDL cholesterol 
and plasma apo B levels on IMT did not reach signiﬁ cance in the diabetic or control 
subjects in this study. Th e use of lipid-lowering drugs was an exclusion criterion for 
participation in our study. Furthermore, plasma lipid cut-oﬀ  values for lipid lowering 
intervention are more stringent for diabetic than for non-diabetic subjects. Th is probably 
resulted in the selection of diabetic participants with relatively low cholesterol levels, 
and may explain why VLDL+LDL cholesterol and apo B were not higher in the diabetic 
patients in the present study. Th is selection could also be responsible for the lack of a 
signiﬁ cant relationship of IMT with these lipid variables.
In the interpretation of the positive eﬀ ect of plasma PLTP activity on IMT in 
type 2 diabetes, it is important that this relationship was not explained by associations 
of PLTP with HDL cholesterol and plasma triglycerides, or by relationships of plasma 
PLTP activity with CRP activity and insulin. Th us, it is unlikely that this relationship 
of plasma PLTP activity with IMT reﬂ ects an association with low-grade inﬂ ammation 
or insulin resistance. In comparison, the only available data so far have demonstrated 
that the eﬀ ect of high plasma PLTP activity on cardiovascular disease is still present 
after controlling for lipid levels [13]. In non-diabetic control subjects, variation in 
IMT appeared to be less pronounced, compared with diabetic patients, and we were 
unable to demonstrate a signiﬁ cant independent eﬀ ect of plasma PLTP activity on 
IMT. Further analyses showed neither an interaction between plasma PLTP activity and 
diabetes mellitus with respect to IMT, nor a non-linear relationship of PLTP with IMT. 
Th erefore, the absence of a signiﬁ cant relationship of IMT with plasma PLTP activity 
in control subjects is unlikely due to a diabetes-speciﬁ c eﬀ ect or to a threshold level of 
plasma PLTP activity level on IMT. Th e lack of such a relationship could be due to 
insuﬃ  cient power. 
Among other possibilities, the observed relationship of plasma PLTP activity 
with carotid artery IMT may be attributable to a change in the quality of LDL. Patients 
with type 2 diabetes have small, dense LDL particles, which are especially prone to 
oxidative modiﬁ cation, and these particles contribute to the progression of coronary 
artery disease [39]. Elevated plasma PLTP activity has been shown to be an independent 
determinant of small, dense LDL in type 2 diabetes mellitus [40]. Increased plasma 
PLTP activity in diabetic patients may cause a redistribution of plasma vitamin E, 
resulting in lowering of the vitamin E content of apo B-containing lipoproteins [41]. 








with the ratio of α-tocopherol to lipid in LDL [41]. Th us, increased sensitivity of LDL 
for oxidation may be an important mechanistic link between elevated plasma PLTP 
activity and increased IMT. 
Finally, it is noteworthy that our study demonstrates that the PLTP-raising eﬀ ect 
of the diabetic state remains after adjustment for waist circumference, plasma lipids, 
CRP and plasma insulin. Possible mechanisms responsible for the independent eﬀ ect of 
the diabetic state in itself on plasma PLTP activity include impaired lowering by insulin 
[15]. Our ﬁ ndings do not support the idea that the higher PLTP activity levels in type 
2 diabetes are due to an association with low-grade inﬂ ammation [19]. Th e inﬂ uence 
of hyperglycaemia on circulating PLTP activity in humans is incompletely understood. 
PLTP release by HepG2 cells may increase in response to glucose in vitro [42]. In 
humans, however, plasma PLTP activity decreases after short-term hyperglycaemia 
independently of insulin [43]. In diabetic patients, we did not observe a relationship of 
plasma PLTP activity with actual glycaemia, but the eﬀ ect of the HbA1c level was close 
to signiﬁ cance. 
In conclusion, this study suggests that the plasma PLTP activity level may 
represent a marker for accelerated atherosclerosis, particularly in type 2 diabetic patients. 
Th us, measurement of plasma PLTP activity could be useful for the stratiﬁ cation of 
cardiovascular risk. 
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